Self-assemblies of azacitidine prodrug: An innovative therapy against myelodysplastic syndromes - Archive ouverte HAL Accéder directement au contenu
Poster De Conférence Année : 2019

Self-assemblies of azacitidine prodrug: An innovative therapy against myelodysplastic syndromes

Résumé

5-azacitidine, a cytidine analogue and a hypomethylating agent, is one of the main drugs being used for the treatment of myelodysplastic syndromes . However after administration, it exhibits several limitations including restricted diffusion and cellular internalization due to its hydrophilicity, and rapid enzymatic degradation. Our objective is to improve the drug diffusion and to protect it from metabolic degradation via the formulation of an amphiphilic prodrug and its self-assembly into a nanoparticle. Following the conjugation of the fatty acid to the azacitidine, the obtained prodrug was solubilized in acetone and mixed with water at different ratios to obtain self-assemblies by nanoprecipitation, thus protecting the active molecule from enzymatic degradation. This prodrug should be cleaved by cathepsin B , an enzyme overexpressed in cancerous cells , thus increasing the specificity of the drug.
Fichier principal
Vignette du fichier
Poster SFNANO 2019 - Milad.pdf (1.06 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02415685 , version 1 (17-12-2019)

Identifiants

  • HAL Id : hal-02415685 , version 1

Citer

Milad Baroud, Elise Lepeltier, Sylvain Thépot, Yolla El Makhour, Olivier Duval. Self-assemblies of azacitidine prodrug: An innovative therapy against myelodysplastic syndromes. SFNano -2019, Dec 2019, Dijon, France. ⟨hal-02415685⟩
116 Consultations
49 Téléchargements

Partager

Gmail Facebook X LinkedIn More